Taysha Gene Therapies, Inc. TSHA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s financing cash flow?
- Taysha Gene Therapies, Inc. (TSHA) reported financing cash flow of $711K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s financing cash flow changed year-over-year?
- Taysha Gene Therapies, Inc.'s financing cash flow increased by 1467.3% year-over-year, from -$52K to $711K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s financing cash flow?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s financing cash flow has grown at a 73.9% compound annual growth rate (CAGR), from $52.2M to $274.59M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.